Literature DB >> 12148896

Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma.

R Lerza1, M Botta, B Barsotti, E Schenone, M Mencoboni, G Bogliolo, I Pannacciulli, E Arboscello.   

Abstract

We report a case of steroid-induced acute tumor lysis syndrome and review the literature. A 60-year-old woman was started on steroid therapy for dyspnea due to bilateral pleural effusion and a large mass involving the anterior mediastinum. The final diagnosis was precursor T-lymphoblastic lymphoma-leukemia. Following steroid therapy, the patient developed acute renal failure and laboratory evidence of metabolic changes induced by massive cytolysis. She received vigorous hydration, diuretic and allopurinol therapy, and haemodialysis. Her diuresis, renal function and laboratory data returned to normal within 2 weeks. A review of the medical literature on T-cell lymphoma revealed only one similar case of steroid-induced acute tumor lysis syndrome, a life-threatening metabolic emergency. This risk should be kept into account in the management of patients with lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12148896     DOI: 10.1080/10428190290021452

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  12 in total

1.  Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma.

Authors:  Zaher K Otrock; Hassan A Hatoum; Ziad M Salem
Journal:  Intern Emerg Med       Date:  2008-02-13       Impact factor: 3.397

2.  Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?

Authors:  Toru Ishikawa
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

Review 3.  Splenic Micronodular T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: The Corticosteroid Pretreatment Hypothesis.

Authors:  Benzion Samueli; Karen Nalbandyan; Daniel Benharroch; Itai Levi
Journal:  Acta Haematol       Date:  2021-11-09       Impact factor: 3.068

4.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

Review 5.  Dexamethasone as an adjuvant to peripheral nerve block.

Authors:  Carolyne Pehora; Annabel Me Pearson; Alka Kaushal; Mark W Crawford; Bradley Johnston
Journal:  Cochrane Database Syst Rev       Date:  2017-11-09

6.  Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.

Authors:  Jin Ok Kim; Dae Won Jun; Hye Jin Tae; Kang Nyeong Lee; Hang Lak Lee; Oh Young Lee; Ho Soon Choi; Byung Chul Yoon; Joon Soo Hahm
Journal:  Clin Mol Hepatol       Date:  2015-03-25

Review 7.  Tumor Lysis-like Syndrome in Eosinophilic Disease of the Lung: A Case Report and Review of the Literature.

Authors:  Seiya Urae; Kayori Tsuruoka; Sayaka Kuroya; Yugo Shibagaki
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

8.  An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature.

Authors:  Yajian Jiang; Wanzhuo Xie; Keyue Hu; Jie Sun; Xiaoli Zhu; He Huang
Journal:  Oncol Lett       Date:  2013-07-29       Impact factor: 2.967

9.  Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Drug Des Devel Ther       Date:  2016-08-12       Impact factor: 4.162

10.  Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).

Authors:  Cody P Coyne; Lakshmi Narayanan
Journal:  Chem Biol Drug Des       Date:  2016-12-20       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.